{"altmetric_id":26768895,"counts":{"readers":{"mendeley":0,"citeulike":0,"connotea":0},"total":{"posts_count":1},"twitter":{"unique_users_count":1,"unique_users":["ChpHealthcare"],"posts_count":1}},"citation":{"authors":["Y Kusano","M Yokoyama","Y Terui","N Inoue","A Takahashi","H Yamauchi","N Tsuyama","N Nishimura","Y Mishima","K Takeuchi","K Hatake"],"doi":"10.1038\/bcj.2017.96","first_seen_on":"2017-09-29T15:14:31+00:00","funders":["niehs"],"handles":[],"isbns":[],"issns":["false","2044-5385"],"issue":"9","journal":"Blood Cancer Journal","last_mentioned_on":1506698055,"links":["http:\/\/www.nature.com\/bcj\/journal\/v7\/n9\/full\/bcj201796a.html?WT.feed_name=subjects_cancer&utm_source=dlvr.it&utm_medium=twitter&foxtrotcallback=true"],"pmid":"28960192","pubdate":"2017-09-01T00:00:00+00:00","publisher":"Nature Publishing Group","publisher_subjects":[{"name":"B-cell lymphoma","scheme":"npg"},{"name":"T cells","scheme":"npg"}],"startpage":"e614","title":"High pretreatment level of soluble interleukin-2 receptor is a robust prognostic factor in patients with follicular lymphoma treated with R-CHOP-like therapy","type":"article","volume":"7"},"altmetric_score":{"score":0.25,"score_history":{"1y":0.25,"6m":0.25,"3m":0.25,"1m":0.25,"1w":0.25,"6d":0.25,"5d":0.25,"4d":0.25,"3d":0,"2d":0,"1d":0,"at":0.25},"context_for_score":null},"demographics":{"poster_types":{"member_of_the_public":1},"users":{"twitter":{"cohorts":{"Members of the public":1}}}},"posts":{"twitter":[{"url":"http:\/\/twitter.com\/ChpHealthcare\/statuses\/913783992628867072","license":"gnip","citation_ids":[26768895],"posted_on":"2017-09-29T15:14:15+00:00","author":{"name":"ChpHealthcare.com","url":"http:\/\/www.chphealthcare.com","image":"https:\/\/pbs.twimg.com\/profile_images\/535842796460965888\/hR1KY45G_normal.png","id_on_source":"ChpHealthcare","tweeter_id":"2905419084","geo":{"lt":null,"ln":null},"followers":254},"tweet_id":"913783992628867072"}]}}